Bellerophon reports positive top-line data from phase 2 acute dose escalation study of inopulse® for treatment of pulmonary hypertension associated with sarcoidosis

Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; company intends to design multi-dose phase 2b trial
BLPH Ratings Summary
BLPH Quant Ranking